OncoSec Medical and Plexxikon Collaborate to Explore Combination Immunotherapy in Preclinical Tumor Studies OncoSec Medical Inc. announced a preclinical collaboration with Plexxikon Inc. to test the combination of Plexxikon’s selective CSF-1R inhibitor with OncoSec’s Immunopulse pIL-12. [OncoSec Medical Inc.] Press Release UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment OncoSec Medical Inc. has entered a clinical collaboration with the University of California, San Francisco to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma. [OncoSec Medical Inc.] Press Release Amgen and AstraZeneca Announce Positive Results from Third and Final Pivotal Phase III Study of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Amgen and AstraZeneca announced that AMAGINE-2TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. [Amgen Inc.] Press Release Regulatory Update on Transaction with Novartis The US Federal Trade Commission has voted to approve GlaxoSmithKline plc. (GSK)’s proposed acquisition of Novartis’s vaccines business (excluding influenza vaccines) and the proposed creation of a consumer healthcare joint venture between GSK and Novartis. [GlaxoSmithKline plc.] Press Release Unum Therapeutics Announces Start of First Phase I Clinical Trial of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Unum Therapeutics announced that recruitment has begun in the first clinical trial of the ATTCK20 therapy. The Phase I study will examine the feasibility, safety and potential efficacy of infusing the ATTCK20 combination therapy in patients with B-cell malignancies and persistent disease following standard therapy. [Unum Therapeutics] Press Release Pluristem Granted Patent in Singapore for its 3D Cell Expansion Technology Pluristem Therapeutics Inc. announced it has been granted a patent in Singapore titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy.” [Pluristem Therapeutics Inc.] Press Release New IMBRUVICA® (Ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom’s Macroglobulinemia Pharmacyclics, Inc. announced the acceptance of a Type II variation application for IMBRUVICA® (ibrutinib) by the European Medicines Agency. This submission represents a potential label expansion for IMBRUVICA in the European Union (EU) for the treatment of adult patients with Waldenstrom’s macroglobulinemia, a rare type of B-cell lymphoma for which treatment options are limited in the EU. [Pharmacyclics, Inc.] Press Release CPRIT Awards UTSW Faculty $22.5 Million for Recruitment and Research in Liver Cancer, Leukemia, and Immunotherapy UT Southwestern Medical Center faculty was awarded seven grants totaling more than $22 million from the Cancer Prevention and Research Institute of Texas (CPRIT) for investigations into leukemia, liver cancer, and immunotherapy, as well as to recruit new faculty. [UT Southwestern Medical Center] Press Release City of Hope Researchers Unlock the Potential of the Immune System to Fight Cancer City of Hope is using chimeric antigen receptor, or CAR-T cell therapy, in clinical trials for leukemia, lymphoma and other hematologic malignancies. [City of Hope] Press Release |